Product News: Mirus to Display Latest Transfection Technology at ASCB 2013

28 Nov 2013

Stop by the 711 (booth #) and tell Mirus about your research! Find out about their newest TRANSFECTION BREAKTHROUGH: TransIT-X2™ Dynamic Delivery System. TransIT-X2 is a new High Performance Broad Spectrum Transfection System, Capable of Delivering DNA and/or siRNA that can be used for independent or simultaneous delivery of DNA and siRNA. TransIT-X2 offers researchers:

- Efficiency—Exceptional broad spectrum transfection
- Versatility—Cutting edge delivery of plasmid DNA and/or siRNA
- Technology—Novel non-liposomal polymeric delivery

“Profound advances in gene delivery technology have been lacking for some time,” said Scott Hayes, Vice President, Mirus Bio LLC. “As a result, researchers have increasingly resorted to virus-borne or physical disruption technologies to facilitate nucleic acid uptake in difficult-to-transfect cell types despite inherent limitations with each of these methods. A better understanding of the barriers to transfection, and ways to overcome them, has led to the development of a new innovative polymeric dynamic delivery system. This system provides superior delivery of plasmid DNA and siRNA into a vast array of cell types. We feel that this technology provides distinct advantages over other means of transfection and opens new avenues for experimental design."

In head-to-head testing, TransIT-X2 outperformed the market leader by at least 2-fold in cell types that include: A549, CHO-K1, Hep G2, HCC1143, HUVEC, LNCaP, MDA-MB-468, MDCK, HMEC, Immortalized Keratinocytes and T47D.

For experimental details and testing results, please visit

Also, stop in to see one of our experts present a seminar on optimizing transfection and updates on more recent issues and solutions delivering to relevant cell types.

Sunday, Dec 15, 6:45-8:15 p.m., Room 212
PERFECTING TRANSFECTION: How to Deliver to Physiological Relevant Cell Types

presented by Anjana Bhattacharya, Ph.D.
Delivery of different nucleic acids such as plasmid DNA, siRNA and mRNA into cells using chemical transfection or electroporation is critical to accelerating cell biology research. In this talk, we will outline current transfection chemistries, their mechanism, and associated cytotoxicity. Cytotoxicity induced gene expression changes can be minimized by choosing the right transfection reagent. Further optimization of key experimental factors is imperative when working with physiological relevant cell types that are hard-to-transfect, e.g. primary and stem cells. Electroporation options will be discussed for cells that are refractory to chemical transfection. Lastly, as nucleic acid delivery using viral vectors remains one of the most efficient methods for transfecting non-dividing primary cells, we will present strategies for optimizing transfections for high-titer virus production.